AU2018276192B2 - Method for producing optically active compound - Google Patents

Method for producing optically active compound Download PDF

Info

Publication number
AU2018276192B2
AU2018276192B2 AU2018276192A AU2018276192A AU2018276192B2 AU 2018276192 B2 AU2018276192 B2 AU 2018276192B2 AU 2018276192 A AU2018276192 A AU 2018276192A AU 2018276192 A AU2018276192 A AU 2018276192A AU 2018276192 B2 AU2018276192 B2 AU 2018276192B2
Authority
AU
Australia
Prior art keywords
group
salt
acid
compound
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018276192A
Other languages
English (en)
Other versions
AU2018276192A1 (en
Inventor
Sayuri HIRANO
Motoki Ikeuchi
Jun-Ichi Kawakami
Masato Kitayama
Koji Nakamoto
Yoshiyuki Takeda
Masatoshi Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dot Therapeutics 1 Inc
Original Assignee
Dot Therapeutics 1 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dot Therapeutics 1 Inc filed Critical Dot Therapeutics 1 Inc
Publication of AU2018276192A1 publication Critical patent/AU2018276192A1/en
Assigned to DOT THERAPEUTICS-1, INC. reassignment DOT THERAPEUTICS-1, INC. Request for Assignment Assignors: MILLENNIUM PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2018276192B2 publication Critical patent/AU2018276192B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2018276192A 2017-05-30 2018-05-29 Method for producing optically active compound Active AU2018276192B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-106280 2017-05-30
JP2017106280 2017-05-30
PCT/IB2018/053822 WO2018220533A2 (ja) 2017-05-30 2018-05-29 光学活性化合物の製造法

Publications (2)

Publication Number Publication Date
AU2018276192A1 AU2018276192A1 (en) 2020-01-16
AU2018276192B2 true AU2018276192B2 (en) 2022-05-19

Family

ID=64454503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018276192A Active AU2018276192B2 (en) 2017-05-30 2018-05-29 Method for producing optically active compound

Country Status (12)

Country Link
US (2) US10988469B2 (https=)
EP (2) EP3632441B1 (https=)
JP (2) JP7102233B2 (https=)
KR (1) KR102754527B1 (https=)
CN (2) CN111032047B (https=)
AU (1) AU2018276192B2 (https=)
CA (1) CA3065683A1 (https=)
EA (1) EA039880B1 (https=)
ES (1) ES2986461T3 (https=)
IL (1) IL270983B (https=)
MX (1) MX391164B (https=)
WO (1) WO2018220533A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391164B (es) 2017-05-30 2025-03-21 Dot Therapeutics 1 Inc Metodo para producir compuesto opticamente activo
CN113557227A (zh) * 2019-03-27 2021-10-26 协和医药化工股份有限公司 前列腺素的制造方法
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
CN114685564B (zh) * 2020-12-27 2023-09-22 西北大学 新型亚磷酰胺配体及其合成方法和应用
EP4377296A1 (en) 2021-07-26 2024-06-05 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法
WO2026028053A2 (en) 2024-07-27 2026-02-05 Assia Chemical Industries Ltd. Process for the preparation of tovorafenib
CN119241530B (zh) * 2024-09-20 2026-04-10 武汉九州钰民医药科技有限公司 一种Tovorafenib的药物合成工艺
CN119241529B (zh) * 2024-09-20 2026-04-10 武汉九州钰民医药科技有限公司 一种Tovorafenib的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006389A2 (en) * 2007-06-29 2009-01-08 Sunesis Pharmaceuticals, Inc. Pyrimidine derivatives useful as raf kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764842B2 (en) * 2001-03-28 2004-07-20 Merck & Co., Inc. Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7754889B2 (en) * 2004-03-29 2010-07-13 Takasago International Corporation Optically active transition metal-diamine compound and process for producing optically active alcohol with the same
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
EP2167497A2 (en) * 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
MX351657B (es) * 2012-03-14 2017-10-23 Merck Sharp & Dohme Sales de alcaloide de cinchona bis-cuaternarias como catalizadores de transferencia de fase asimétrica.
CN107880075A (zh) 2012-03-28 2018-04-06 武田药品工业株式会社 铑催化剂和制备胺化合物的方法
TWI602803B (zh) * 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
WO2015178846A1 (en) * 2014-05-20 2015-11-26 Sp Process Development Ab Process for the preparation of chiral amines from prochiral ketones
JP6638363B2 (ja) 2015-12-11 2020-01-29 株式会社大林組 掘削装置および杭孔の拡径方法
CN105524111B (zh) * 2016-01-25 2017-10-27 西北农林科技大学 手性亚磷酰胺单齿配体及其合成方法与应用
MX391164B (es) 2017-05-30 2025-03-21 Dot Therapeutics 1 Inc Metodo para producir compuesto opticamente activo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006389A2 (en) * 2007-06-29 2009-01-08 Sunesis Pharmaceuticals, Inc. Pyrimidine derivatives useful as raf kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIANG XIAO-BIN ET AL, "Application of monodentate secondary phosphine oxides, a new class of chiral ligands, in Ir(i)-catalyzed asymmetric imine hydrogenation", ORGANIC LETTERS, AMERICAN CHEMICAL SOCIETY, vol. 5, no. 9, pages 1503 - 1506 *
T. NUGENT ET AL, "Chiral Amine Synthesis - Recent Developments and Trends for Enamide Reduction, Reductive Amination, and Imine Reduction", ADVANCED SYNTHESIS & CATALYSIS, vol. 352, no. 5, pages 753 - 819, doi:10.1002/adsc.200900719 *

Also Published As

Publication number Publication date
EP3632441A2 (en) 2020-04-08
JP7420865B2 (ja) 2024-01-23
MX391164B (es) 2025-03-21
IL270983B (en) 2022-03-01
US20210347769A1 (en) 2021-11-11
KR102754527B1 (ko) 2025-01-14
JP2018203733A (ja) 2018-12-27
EP4406609A3 (en) 2024-10-02
AU2018276192A1 (en) 2020-01-16
EP4406609A2 (en) 2024-07-31
US20200317659A1 (en) 2020-10-08
MX2019014256A (es) 2022-03-31
JP7102233B2 (ja) 2022-07-19
KR20200013707A (ko) 2020-02-07
CN117447464A (zh) 2024-01-26
EP3632441A4 (en) 2021-01-13
WO2018220533A3 (ja) 2019-02-28
ES2986461T3 (es) 2024-11-11
CN111032047A (zh) 2020-04-17
EA201992709A1 (ru) 2020-04-23
WO2018220533A2 (ja) 2018-12-06
CA3065683A1 (en) 2018-12-06
EP3632441C0 (en) 2024-07-17
CN111032047B (zh) 2023-10-27
BR112019025355A2 (pt) 2020-06-23
JP2022116043A (ja) 2022-08-09
US10988469B2 (en) 2021-04-27
EA039880B1 (ru) 2022-03-23
US12129249B2 (en) 2024-10-29
EP3632441B1 (en) 2024-07-17
IL270983A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
AU2018276192B2 (en) Method for producing optically active compound
CN111417618B (zh) 用于制备富含对映异构体和非对映异构体的环丁烷胺和环丁烷酰胺的方法
US20180079741A1 (en) Process for producing heterocyclic compound
CA3044501A1 (en) Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof
JP6476497B2 (ja) 光学活性化合物の製造方法、及び新規な金属−ジアミン錯体
HK40114634A (en) Method for producing optically active compound
Zhao et al. Enantioselective Michael addition of 3-aryloxindoles to a vinyl bisphosphonate ester catalyzed by a cinchona alkaloid derived thiourea catalyst
HK40022701A (en) Method for producing optically active compound
Belokon et al. Novel type of trifunctional chiral N-heterocyclic carbene (NHC) precursors
BR112019025355B1 (pt) Métodos para a produção de compostos oticamente ativos, composto e forma oticamente ativa
JPWO2013027835A1 (ja) 光学活性ナフタレン化合物の製法
CN115028633A (zh) 吡咯并嘧啶类化合物的制备及其应用
HK40022701B (en) Method for producing optically active compound
JP4861317B2 (ja) ２，３−ジアミノプロピオン酸誘導体のエナンチオマー体の製造方法。
Chiang Synthesis, characterization and catalytic application of novel cyclopalladated pyridine functionalized N-heterocyclic carbene complexes

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DOT THERAPEUTICS-1, INC.

Free format text: FORMER APPLICANT(S): MILLENNIUM PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)